Stockscreener 앱 받기
21.70
8.61%
1.72
시간 외 거래:
21.76
0.06
+0.28%
전일 마감가:
$19.98
열려 있는:
$19.96
하루 거래량:
177.80K
Relative Volume:
0.78
시가총액:
$1.49B
수익:
-
순이익/손실:
$-48.26M
주가수익비율:
-27.47
EPS:
-0.7899
순현금흐름:
$-45.04M
1주 성능:
+6.58%
1개월 성능:
+1.45%
6개월 성능:
+71.00%
1년 성능:
+80.98%
1일 변동 폭
$19.96
$21.77
1주일 범위
$19.52
$22.06
52주 변동 폭
$11.32
$25.94
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
21.70 | 1.40B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-06-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2025-03-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-02-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 개시 | H.C. Wainwright | Buy |
| 2022-06-16 | 개시 | ROTH Capital | Buy |
모두보기
Gh Research Plc 주식(GHRS)의 최신 뉴스
(GHRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
GH Research (GHRS) Bounces 2.23% as Shares Test Key Resistance at $22.18Exhaustion Gap - newsline.com
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower-Than-Expected Operating Loss Amid Pipeline ProgressEarnings Power Value - newsline.com
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy? - simplywall.st
GH Research PLC (GHRS) Gains Ground After Testing Support, Resistance in FocusAscending Triangle - newsline.com
GH Research Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical DevelopmentReturn On Assets - newsline.com
GHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS) - Insider Monkey
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
GH Research earnings ahead: Can cash sustain Phase 3 ambitions? - Investing.com
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
(GHRS) Risk Channels and Responsive Allocation - Stock Traders Daily
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression - Stock Titan
GH Research publishes phase 2a postpartum depression results By Investing.com - Investing.com Australia
GH Research publishes phase 2a postpartum depression results - Investing.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results - Yahoo Finance UK
GHRS Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Deepens R&D InvestmentFinancial Health Score - newsline.com
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - AOL.com
GH Research (GHRS) Surges Over 7%: Testing Key Resistance at $25.19Chandelier Stop - newsline.com
GH Research (GHRS) Surges 7.19% as Breakout Above $25.19 Resistance Becomes Key TestOvernight Profile - The Legal Advocate
Certain Options of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
GHRS Q1 2026 Earnings: Wider-than-Expected Loss Underscores Clinical-Stage ChallengesEarnings Miss Streak - newsline.com
GH Research (GHRS) Jumps 3.35% as Shares Approach Key Resistance at $24.0Insider Selling Alerts - The Legal Advocate
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research Stock Moves as Market Eyes Data in Holiday Week - Bez Kabli
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression - Sahm
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression - Stock Titan
[EFFECT] GH Research PLC SEC Filing - Stock Titan
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) - Seeking Alpha
GHRS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers GH Research stock price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright lowers GH Research stock price target on dilution - Investing.com
Lynx1 and Weston Nichols report 17.4% stake in GH Research (NASDAQ: GHRS) - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS) - simplywall.st
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans - Yahoo Finance
GHRS SEC FilingsGh Research Plc 10-K, 10-Q, 8-K Forms - Stock Titan
GHRS Maintained by Cantor Fitzgerald -- Price Target Raised to $35 - GuruFocus
Lynx1 discloses 15.2% stake in GHRS (GHRS) via Schedule 13G/A - Stock Titan
GHRS Maintained by CitizensPrice Target Lowered to $39.00 - GuruFocus
Cantor Fitzgerald raises GH Research stock price target on adoption outlook - Investing.com UK
These Analysts Revise Their Forecasts On GH Research After Q1 Results - Benzinga
Canaccord reiterates GH Research stock rating on phase 3 progress By Investing.com - Investing.com Nigeria
Cantor Fitzgerald raises GH Research stock price target on adoption outlook By Investing.com - Investing.com South Africa
Gh Research Plc (GHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):